Internet Archive Scholar

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy

Irene Pachón-Angona, Bernard Refouvelet, Rudolf Andrýs, Helène Martin, Vincent Luzet, Isabel Iriepa, Ignacio Moraleda, Daniel Diez-Iriepa, María-Jesús Oset-Gasque, José Marco-Contelles, Kamil Musilek, Lhassane Ismaili
2019 Figshare  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.1 MB)
https://web.archive.org/web/20200221201247/https://s3-eu-west-1.amazonaws.com/pstorage-tf-iopjsd8797887/14243999/ienz_a_1545766_sm2711.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test).
more » ... sequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
doi:10.6084/m9.figshare.7667057 fatcat:ivnoxhracbeyxbmzggjcni23te
Open Access
Citation

Irene Pachón-Angona, Bernard Refouvelet, Rudolf Andrýs, Helène Martin, Vincent Luzet, Isabel Iriepa, Ignacio Moraleda, Daniel Diez-Iriepa, María-Jesús Oset-Gasque, José Marco-Contelles, Kamil Musilek, Lhassane Ismaili. "Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy." Figshare (2019)